<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological treatment for pain in Guillain‐Barré syndrome - Liu, J - 2015 | Cochrane Library</title> <meta content="Pharmacological treatment for pain in Guillain‐Barré syndrome - Liu, J - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009950.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological treatment for pain in Guillain‐Barré syndrome - Liu, J - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009950.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009950.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological treatment for pain in Guillain‐Barré syndrome" name="citation_title"/> <meta content="Jia Liu" name="citation_author"/> <meta content="Xuanwu Hospital, Capital Medical University" name="citation_author_institution"/> <meta content="Jason_liu1984@163.com" name="citation_author_email"/> <meta content="Lu‐Ning Wang" name="citation_author"/> <meta content="Chinese PLA General Hospital" name="citation_author_institution"/> <meta content="Ewan D McNicol" name="citation_author"/> <meta content="Tufts Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD009950.pub3" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/04/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009950.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009950.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009950.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amines [adverse effects, therapeutic use]; Analgesics [adverse effects, *therapeutic use]; Carbamazepine [adverse effects, therapeutic use]; Constipation [chemically induced]; Cyclohexanecarboxylic Acids [adverse effects, therapeutic use]; Gabapentin; Guillain‐Barre Syndrome [*complications]; Immunoglobulins, Intravenous [therapeutic use]; Methylprednisolone [therapeutic use]; Nausea [chemically induced]; Pain [complications, *drug therapy]; Pain Measurement; Randomized Controlled Trials as Topic; gamma‐Aminobutyric Acid [adverse effects, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009950.pub3&amp;doi=10.1002/14651858.CD009950.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="tkZQC4GK";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009950\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009950\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009950\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009950\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","pt","hr","zh_HANS","fa","th"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009950.pub3",title:"Pharmacological treatment for pain in Guillain\\u2010Barr\\u00E9 syndrome",firstPublishedDate:"Apr 9, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neuromuscular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009950.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009950.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009950.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009950.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009950.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009950.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009950.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009950.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009950.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009950.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4227 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009950.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/full#CD009950-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/full#CD009950-sec-0093"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/full#CD009950-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/full#CD009950-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/full#CD009950-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/full#CD009950-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/full#CD009950-sec-0066"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/full#CD009950-sec-0087"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/appendices#CD009950-sec-0097"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological treatment for pain in Guillain‐Barré syndrome</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/information#CD009950-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Jia Liu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/information#CD009950-cr-0003">Lu‐Ning Wang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009950.pub3/information#CD009950-cr-0004">Ewan D McNicol</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/information/en#CD009950-sec-0106">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 April 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009950.pub3">https://doi.org/10.1002/14651858.CD009950.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009950-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009950-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009950-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009950-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pt#CD009950-abs-0002">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD009950-abs-0013">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009950-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009950-abs-0001" lang="en"> <section id="CD009950-sec-0001"> <h3 class="title" id="CD009950-sec-0001">Background</h3> <p>Pain in Guillain‐Barré syndrome (GBS) is common, yet it is often under recognised and poorly managed. In recent years, a variety of pharmacological treatment options have been investigated in clinical trials for people with GBS‐associated pain. This is an updated version of the original Cochrane review published in Issue 10, 2013. </p> </section> <section id="CD009950-sec-0002"> <h3 class="title" id="CD009950-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of pharmacological treatments for various pain symptoms associated with GBS, during both the acute and convalescent (three months or more after onset) phases of GBS. </p> </section> <section id="CD009950-sec-0003"> <h3 class="title" id="CD009950-sec-0003">Search methods</h3> <p>On 3 November 2014, we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE and EMBASE. In addition, we searched ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform. </p> </section> <section id="CD009950-sec-0004"> <h3 class="title" id="CD009950-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and quasi‐RCTs in participants with confirmed GBS, with pain assessment as either the primary or secondary outcome. For cross‐over trials, an adequate washout period between phases was required for inclusion. </p> </section> <section id="CD009950-sec-0005"> <h3 class="title" id="CD009950-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened the titles and abstracts of identified records, selected studies for inclusion, extracted eligible data, cross‐checked the data for accuracy and assessed the risk of bias of each study. </p> </section> <section id="CD009950-sec-0006"> <h3 class="title" id="CD009950-sec-0006">Main results</h3> <p>Three short‐term RCTs, which enrolled 277 randomised participants with acute phase GBS, were included. Risk of bias in the included studies was generally unclear due to insufficient information. None of the included studies reported the primary outcome selected for this review, which was number of patients with self reported pain relief of 50% or greater. One small study investigated seven‐day regimens of gabapentin versus placebo. Pain was rated on a scale from 0 (no pain) to 10 (maximum pain). Amongst the 18 participants, significantly lower mean pain scores were found at the endpoint (day 7) in the gabapentin phase compared to the endpoint of the placebo phase (mean difference ‐3.61, 95% CI ‐4.12 to ‐3.10) (very low quality evidence). For adverse events, no significant differences were found in the incidence of nausea (risk ratio (RR) 0.50, 95% CI 0.05 to 5.04) or constipation (RR 0.14, 95% CI 0.01 to 2.54). A second study enrolling 36 participants compared gabapentin, carbamazepine and placebo, all administered over seven days. Participants in the gabapentin group had significantly lower median pain scores on all treatment days in comparison to the placebo and carbamazepine groups (P &lt; 0.05). There were no statistically significant differences in the median pain scores between the carbamazepine and placebo groups from day 1 to day 3, but from day 4 until the end of the study significantly lower median pain scores were noted in the carbamazepine group (P &lt; 0.05) (very low quality evidence). There were no adverse effects of gabapentin or carbamazepine reported, other than sedation. One large RCT (223 participants, all also treated with intravenous immunoglobulin), compared a five‐day course of methylprednisolone with placebo and found no statistically significant differences in number of participants developing pain (RR 0.89, 95% CI 0.68 to 1.16), number of participants with decreased pain (RR 0.95, 95% CI 0.63 to 1.42) or number of participants with increased pain (RR 0.85, 95% CI 0.52 to 1.41) (low quality evidence). The study did not report whether there were any adverse events. </p> </section> <section id="CD009950-sec-0007"> <h3 class="title" id="CD009950-sec-0007">Authors' conclusions</h3> <p>Since the last version of this review we found no new studies. While management of pain in GBS is essential and pharmacotherapy is widely accepted as being an important component of treatment, this review does not provide sufficient evidence to support the use of any pharmacological intervention in people with pain in GBS. Although reductions in pain severity were found when comparing gabapentin and carbamazepine with placebo, the evidence was limited and its quality very low. Larger, well‐designed RCTs are required to further investigate the efficacy and safety of potential interventions for patients with pain in GBS. Additionally, interventions for pain in the convalescent phase of GBS should be investigated. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009950-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009950-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009950-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009950-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009950-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD009950-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009950-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD009950-abs-0014">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009950-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009950-abs-0004" lang="en"> <h3>Drug treatment for pain in Guillain‐Barré syndrome</h3> <p><b>Review question</b> </p> <p>Our aim in this review was to find out whether medicines for pain in Guillain‐Barré syndrome (GBS) are safe and effective. </p> <p><b>Background</b> </p> <p>GBS is a rare disease that affects the nerves and nerve roots outside the brain and spinal cord. It occurs when the person's immune system attacks the nerves. The trigger is sometimes an infection. Pain in GBS is often under recognised and poorly managed. </p> <p><b>Study characteristics</b> </p> <p>We first carried out a wide search of medical databases to find studies that met the requirements for this review. We identified three studies, which involved 277 participants who were randomly assigned to different treatments for pain in GBS. Two studies compared a pain medicine (gabapentin or carbamazepine) with placebo (inactive treatment). The other study compared a steroid medicine with placebo. </p> <p><b>Key results and quality of the evidence</b> </p> <p>Two medicines, gabapentin and carbamazepine, reduced pain severity compared to placebo (inactive) treatment and they had few side effects. One study found that people taking gabapentin had less pain, sleepiness or need for additional pain killers than those given carbamazepine. However, these studies were small and the treatment period was short. One trial, with 223 participants, found that methylprednisolone, which is a steroid medicine, did not affect the numbers of people who developed pain or change the numbers with more pain or less pain compared with placebo. This study did not report whether there were any side effects. </p> <p>This review does not provide enough evidence to say whether or not treatments for pain in people with GBS work. Although both gabapentin and carbamazepine reduced the severity of pain compared to placebo, and few side effects were reported, the studies were small and the quality of the evidence was very low. Much larger, well‐designed studies are needed to confirm that drug treatments are safe and effective for people with pain in the period soon after onset of GBS. Long‐term studies of pain treatments at the stage when people with GBS are recovering should also be conducted and these should include assessment of effects of pain treatments on quality of life. </p> <p>This review was first published in 2013 and an updated search in 2014 revealed no additional studies. The evidence is current to November 2014. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009950-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009950-sec-0093"></div> <h3 class="title" id="CD009950-sec-0094">Implications for practice</h3> <section id="CD009950-sec-0094"> <p>Since the last version of this review we found no new studies. While management of pain in GBS is essential, and pharmacotherapy is widely accepted as being an important component of treatment, this review did not find sufficient high quality evidence investigating the use of any pharmacological intervention in people with pain in GBS. Although reductions in pain severity were found when comparing gabapentin and carbamazepine with placebo, the evidence was limited and its quality was generally very low. </p> </section> <h3 class="title" id="CD009950-sec-0095">Implications for research</h3> <section id="CD009950-sec-0095"> <p>Large, well‐designed RCTs are required to further investigate the efficacy and safety of potential interventions, such as gabapentin and carbamazepine, for patients with pain in GBS. Additionally, interventions for pain in the convalescent phase of GBS should be investigated. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009950-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009950-sec-0036"></div> <div class="table" id="CD009950-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Gabapentin compared with placebo for pain in Guillain‐Barré syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Gabapentin compared with placebo for pain in Guillain‐Barré syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with pain in Guillain‐Barré syndrome </p> <p><b>Settings:</b> intensive care units in India </p> <p><b>Intervention:</b> gabapentin </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Gabapentin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of patients with self reported pain relief of 50% or greater (not measured)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain score</b> </p> <p>(numerical rating scale of 0 to 10: 0 = no pain, 10 = worst pain)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, mean pain scores decreased from 7.83 ± 0.78 (SD) at baseline (day 0) to 5.67 ± 0.91 on day 7. </p> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median pain scores decreased from 8.0 (1.0 (IQR)) at baseline (day 0) to 6.0 (1.8) on day 7. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, mean pain scores decreased from 7.22 ± 0.83 at baseline to 2.06 ± 0.63 on day 7. </p> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median pain scores decreased from 8.0 (1.0) at baseline (day 0) to 2.0 (0.8) on day 7. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a> </p> <p>mean difference‐3.61 (‐4.12 to ‐3.1) on day 7</p> <p><a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a> </p> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gabapentin superior to placebo in reducing pain scores</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sedation score</b> </p> <p>(numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, mean sedation scores changed from 1.44 ± 0.51 (SD) at baseline (day 0) to 3.63 ± 0.51 on day 7. </p> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median sedation scores changed from 1.0 (1.0 (IQR)) at baseline (day 0) to 4.0 (1.0) on day 7. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, mean sedation scores changed from 1.38 ± 0.50 at baseline to 2.44 ± 0.50 on day 7. </p> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median sedation scores changed from 2.0 (1.0) at baseline to 2.0 (0.0) on day 7. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a> </p> <p>mean difference ‐1.19 (‐1.52 to ‐0.86) on day 7</p> <p><a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a> </p> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gabapentin superior to placebo in reducing sedation scores</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rescue analgesic consumption</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, mean fentanyl consumption change from day 1 to day 7 was ‐3 µg. </p> <p>At day 7, mean fentanyl consumption was 317 ± 24 µg</p> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, mean fentanyl consumption change from day 1 to day 7 was ‐240 µg.<br/> At day 7, mean fentanyl consumption was 351 ± 34 µg. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, mean fentanyl consumption change from day 1 to day 7 was ‐146 µg. </p> <p>At day 7, mean fentanyl consumption was 66 ± 16 µg</p> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, mean fentanyl consumption change from day 1 to day 7 was ‐214 µg. </p> <p>At day 7, mean fentanyl consumption was 126 ± 26 µg.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a> </p> <p>mean difference ‐251 mcg (‐265 to ‐238 mcg) on day 7</p> <p><a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a> </p> <p>‐225 mcg (‐249 to ‐200 mcg) on day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gabapentin superior to placebo in reducing fentanyl consumption</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>111 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b><br/> (6 to 560) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.50 (0.05 to 5.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, no significant<br/> difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Constipation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><br/> (2 to 423) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.14 (0.01 to 2.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, no significant<br/> difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IQR</b> : interquartile range; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Insufficient information for random sequence generation and allocation concealment was provided. </p> <p><sup>2</sup> Insufficient information to assess adequacy of methods to ensure blinding. </p> <p><sup>3</sup> Only 54 participants. </p> <p><sup>4</sup> Only 18 participants. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009950-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Carbamazepine compared with placebo for pain in Guillain‐Barré syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Carbamezapine compared with placebo for pain in Guillain‐Barré syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with pain in Guillain‐Barré syndrome </p> <p><b>Settings:</b> intensive care units in India </p> <p><b>Intervention:</b> carbamazepine </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Carbamazepine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of patients with self reported pain relief of 50% or greater (not measured)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain score</b> </p> <p>(numerical rating scale of 0 to 10: 0 = no pain, 10 = worst pain)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median pain scores decreased from 8.0 (1.0 (IQR) at baseline (day 0) to 6.0 (1.8) on day 7. </p> <p>Median daily scores from day 1 to 7 were 4.0, 4.0, 4.0, 6.0, 6.0, 6.0, and 6.0, respectively).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median pain scores decreased from 8.0 (1.0) at baseline to 3.0 (1.0) on day 7. </p> <p>Daily scores from day 1 to 7 (3.0, 3.0, 3.0, 4.0, 4.0, 3.5, and 3.0, respectively) were significantly lower than placebo from day 4 onwards (P &lt; 0.05). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sedation score</b> </p> <p>(numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median sedation scores changed from 1.0 (1.0 IQR) at baseline (day 0) to 4.0 (1.0) on day 7. </p> <p>Median daily scores from day 1 to 7 were 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, and 4.0, respectively.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median sedation scores changed from 2.0 (1.0) at baseline to 3.0 (1.0) on day 7. </p> <p>Daily scores from day 1 to 7 (3.0, 3.0, 3.0, 3.5, 3.0, 3.0, and 3.0, respectively) were significantly lower than placebo on all days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rescue analgesic consumption</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, mean fentanyl consumption change from day 1 to day 7 was ‐240 µg. </p> <p>At day 7, mean fentanyl consumption was 351 ± 34 µg.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, mean fentanyl consumption change from day 1 to day 7 was ‐ 173 µg. </p> <p>At day 7, mean fentanyl consumption was 174 ± 30 µg.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean difference ‐176 µg (‐202 to ‐150 µg) on day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative effect was calculated at the endpoint. Carbamazepine is superior to placebo in reducing fentanyl consumption </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IQR</b> : interquartile range; <b>SD</b>: standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Insufficient information for random sequence generation and allocation concealment was provided. </p> <p><sup>2</sup> Insufficient information to assess adequacy of methods to ensure blinding. </p> <p><sup>3</sup> Only 24 participants. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009950-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Methylprednisolone compared with placebo for pain in Guillain‐Barré syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous immunoglobulin (IVIg) and methylprednisolone compared with IVIg and placebo for pain in Guillain‐Barré syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Guillain‐Barré syndrome, with varying severities of pain </p> <p><b>Settings:</b> hospitals in the Netherlands </p> <p><b>Intervention:</b> IVIg and methylprednisolone </p> <p><b>Comparison:</b> IVIg and placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>IVIg/placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>IVIg/methylprednisolone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of patients with self reported pain relief of 50% or greater (not measured)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with pain after 4 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>518 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>459 per 1000</b><br/> (352 to 601) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.89 (0.68 to 1.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant<br/> difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with decreased pain after 4 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>304 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>288 per 1000</b><br/> (191 to 431) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.95 (0.63 to 1.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant<br/> difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with increased pain after 4 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>232 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>197 per 1000</b><br/> (121 to 327) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.85 (0.52 to 1.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant<br/> difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IQR</b> : interquartile range; <b>IVIg:</b> intravenous immunoglobulin; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Insufficient information to assess adequacy of methods to ensure blinding. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009950-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Gabapentin compared with carbamazepine for pain in Guillain‐Barré syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Gabapentin compared with carbamazepine for pain in Guillain‐Barré syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> intensive care unit in India </p> <p><b>Settings:</b> intensive care unit in India </p> <p><b>Intervention:</b> gabapentin </p> <p><b>Comparison:</b> carbamazepine </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Carbamazepine</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Gabapentin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of patients with self reported pain relief of 50% or greater (not measured)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain score</b> </p> <p>(numerical rating scale of 0 to 10: 0 = no pain, 10 = worst pain)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median pain scores from day 1 to day 7 were 6.0, 6.0, 5.0, 4.0, 4.0, 3.5, and 3.0, respectively. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median pain scores from day 1 to day 7 (3.5, 2.5, 2.0, 2.0, 2.0, 2.0, and 2.0) were significantly lower versus carbamazepine on each day (P &lt; 0.05). </p> <p>Baseline pain scores were similar between groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gabapentin may be superior to carbamazepine in reducing pain scores</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sedation score</b> </p> <p>(numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median sedation scores from day 1 to day 7 were 2.0, 3.0, 3.0, 3.0, 3.5, 3.0, 3.0, and 3.0, respectively. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median sedation scores from day 1 to day 7 (2.0, 2.0, 2.0, 2.0, 2.0, 2.0, and 2.0, respectively) were significantly lower versus carbamazepine on each day (P &lt; 0.05). </p> <p>Baseline sedation scores were similar between groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gabapentin may be superior to carbamazepine in reducing sedation scores</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rescue analgesic consumption</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, mean fentanyl consumption change from day 1 to day 7 was ‐173 µg. </p> <p>At endpoint (day 7), mean fentanyl consumption was 174±30 µg.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, mean fentanyl consumption change from day 1 to 7 was ‐ 214 µg. </p> <p>At day 7, mean fentanyl consumption was 126 ± 26 µg.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean difference ‐48 µg (‐71 to ‐126 µg) on day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative effect was calculated at the endpoint. Gabapentin is superior to carbamazepine in reducing sedation scores </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Insufficient information for random sequence generation and allocation concealment was provided. </p> <p><sup>2</sup> Insufficient information to assess adequacy of methods to ensure blinding. </p> <p><sup>3</sup> Only 24 participants. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009950-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009950-sec-0037"></div> <p>This review is an update of a previously published review in The Cochrane Database of Systematic Reviews (Issue 10, 2013), "Pharmacological treatment for pain in Guillain‐Barré syndrome". </p> <section id="CD009950-sec-0038"> <h3 class="title" id="CD009950-sec-0038">Description of the condition</h3> <p>Guillain‐Barré syndrome (GBS) is an acute immune‐mediated polyradiculoneuropathy with a worldwide annual incidence of around one case per 100,000, with approximately one‐third of all cases triggered by <i>Campylobacter jejuni</i> infection (<a href="./references#CD009950-bbs2-0022" title="IsraeliE , Agmon‐LevinN , BlankM , ChapmanJ , ShoenfeldY . Guillain‐Barré syndrome‐a classical autoimmune disease triggered by infection or vaccination. Clinical Reviews in Allergy and Immunology2012;42(2):121‐30. ">Israeli 2012</a>; <a href="./references#CD009950-bbs2-0023" title="McGroganA , MadleGC , SeamanHE , deVriesCS . The epidemiology of Guillain‐Barré syndrome worldwide. A systematic literature review. Neuroepidemiology2009;32(2):150‐63. ">McGrogan 2009</a>). Other causes may include vaccination or surgery (<a href="./references#CD009950-bbs2-0022" title="IsraeliE , Agmon‐LevinN , BlankM , ChapmanJ , ShoenfeldY . Guillain‐Barré syndrome‐a classical autoimmune disease triggered by infection or vaccination. Clinical Reviews in Allergy and Immunology2012;42(2):121‐30. ">Israeli 2012</a>). At least four subtypes of GBS exist, including acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor axonal neuropathy (AMAN), acute motor sensory axonal neuropathy (AMSAN) and Miller Fisher syndrome (<a href="./references#CD009950-bbs2-0020" title="HughesRA , CornblathDR . Guillain‐Barré syndrome. Lancet2005;366(9497):1653‐66. ">Hughes 2005a</a>). Pain is a symptom common to all subtypes, occurring in up to 89% of patients during the course of the disease (<a href="./references#CD009950-bbs2-0027" title="MoulinDE , HagenN , FeasbyTE , AmirehR , HahnA . Pain in Guillain‐Barré syndrome. Neurology1997;48(2):328‐31. ">Moulin 1997</a>). Possible mechanisms of pain in GBS include inflammation and compression of nerve roots leading to radicular pain, and demyelination and degeneration of sensory nerves, which alter the balance of sensory input from myelinated and unmyelinated fibres to the dorsal horn of the spinal column (<a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>). There are different kinds of pain involved in GBS, such as neuropathic pain, musculoskeletal pain and visceral pain (<a href="./references#CD009950-bbs2-0028" title="PentlandB , DonaldSM . Pain in the Guillain‐Barré syndrome: a clinical review. Pain1994;59(2):159‐64. ">Pentland 1994</a>). The intensity of pain may be severe in the acute phase (<a href="./references#CD009950-bbs2-0031" title="RutsL , DrenthenJ , JongenJL , HopWC , VisserGH , JacobsBC , et al. Dutch GBS Study Group. Pain in Guillain‐Barré syndrome: a long‐term follow‐up study. Neurology2010;75(16):1439‐47. ">Ruts 2010</a>). In a prospective study, the percentage of patients reporting pain decreased significantly between the two‐week (71%) and two‐month (50%) evaluations. However, up to one‐third of patients still suffered from painful symptoms two years after onset of the syndrome (<a href="./references#CD009950-bbs2-0005" title="ForsbergA , PressR , EinarssonU , dePedro‐CuestaJ , Widén HolmqvistL , Swedish Epidemiological Study Group. Impairment in Guillain‐Barré syndrome during the first 2 years after onset: a prospective study. Journal of the Neurological Sciences2004;227(1):131‐8. ">Forsberg 2004</a>). </p> </section> <section id="CD009950-sec-0039"> <h3 class="title" id="CD009950-sec-0039">Description of the intervention</h3> <p>The most commonly prescribed analgesics are nonsteroidal anti‐inflammatory drugs (NSAIDs) and opioids. Anticonvulsants and antidepressants are also very commonly used by specialists. However, NSAIDs and opioids are not uniformly effective for pain symptoms evoked by different mechanisms, and safety concerns such as gastrointestinal bleeding in those receiving NSAIDs or addiction in those receiving opioids may limit their usefulness. The NSAIDs, such as aspirin, appear to be effective only for muscle and joint pain in GBS (<a href="./references#CD009950-bbs2-0028" title="PentlandB , DonaldSM . Pain in the Guillain‐Barré syndrome: a clinical review. Pain1994;59(2):159‐64. ">Pentland 1994</a>). Epidural opioids have been shown to be effective in GBS, even against burning pain (<a href="./references#CD009950-bbs2-0017" title="EnnisJH . Opioid analgesics and the burning pain of Guillain‐Barré syndrome. Anesthesiology1991;75(5):913‐4. ">Ennis 1991</a>). Case studies have reported that capsaicin may also be effective (<a href="./references#CD009950-bbs2-0007" title="MorgenlanderJC , HurwitzBJ , MasseyEW . Capsaicin for the treatment of pain in Guillain‐Barré syndrome. Annals of Neurology1990;28(2):199. ">Morgenlander 1990</a>), while corticosteroids have not been shown to reduce pain (<a href="./references#CD009950-bbs2-0003" title="RutsL , vanKoningsveldR , JacobsBC , vanDoornPA . Determination of pain and response to methylprednisolone in Guillain‐Barré syndrome. Journal of Neurology2007;254(10):1318‐22. [PUBMED: 17426908] ">Ruts 2007</a>). Evidence suggests that anticonvulsants and antidepressants are more effective than the traditional analgesics for treating neuropathic pain; therefore they may be effective for neuropathic components of pain in GBS (<a href="./references#CD009950-bbs2-0025" title="MooreRA , WiffenPJ , DerryS , McQuayHJ . Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2] ">Moore 2011</a>; <a href="./references#CD009950-bbs2-0026" title="MooreRA , DerryS , AldingtonD , ColeP , WiffenPJ . Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2] ">Moore 2012</a>). </p> </section> <section id="CD009950-sec-0040"> <h3 class="title" id="CD009950-sec-0040">How the intervention might work</h3> <p>NSAIDs inhibit both cyclo‐oxygenase‐1 and cyclo‐oxygenase‐2, preventing the production of prostaglandins which cause pain and inflammation (<a href="./references#CD009950-bbs2-0029" title="PetersonK , McDonaghM , ThakurtaS , DanaT , RobertsC , ChouR , et al. Drug class review: cyclo‐oxygenase (COX)‐2 inhibitors and non‐steroidal anti‐inflammatory drugs (NSAIDs): final update 4 report. www.ncbi.nlm.nih.gov/books/NBK53955/ (accessed 17 January 2012). ">Peterson 2010</a>). Opioids act directly on the nervous system through binding to specific opioid receptors to reduce pain (<a href="./references#CD009950-bbs2-0036" title="ZöllnerC , SchäferM . Opioids in anesthesia. Anaesthesist2008;57(7):729‐40. ">Zöllner 2008</a>). Capsaicin is believed to reduce pain sensitivity through depletion of substance P and defunctionalisation of nociceptor fibres (<a href="./references#CD009950-bbs2-0011" title="AnandP , BleyK . Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high‐concentration capsaicin 8% patch. British Journal of Anaesthesia2011;107(4):490‐502. ">Anand 2011</a>). Corticosteroids are thought to reduce inflammation of the perineurium and epineurium in GBS (<a href="./references#CD009950-bbs2-0014" title="BercianoJ , GarcíaA , FigolsJ , MuñozR , BercianoMT , LafargaM . Perineurium contributes to axonal damage in acute inflammatory demyelinating polyneuropathy. Neurology2000;55(4):552‐9. ">Berciano 2000</a>). For anticonvulsant drugs, the mechanisms of analgesic action remain poorly understood. Possible explanations include that they enhance γ‐aminobutyric acid (GABA) inhibition, have a stabilising effect on neuronal cell membranes, and block new synapse formation (<a href="./references#CD009950-bbs2-0013" title="BennettMI , SimpsonKH . Gabapentin in the treatment of neuropathic pain. Palliative Medicine2004;18(1):5‐11. ">Bennett 2004</a>; <a href="./references#CD009950-bbs2-0018" title="ErogluC , AllenNJ , SusmanMW , O'RourkeNA , ParkCY , OzkanE , et al. Gabapentin receptor alpha2delta‐1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell2009;139(2):380‐92. ">Eroglu 2009</a>; <a href="./references#CD009950-bbs2-0035" title="WoolfCJ , MannionR . Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet1999;353(9168):1959‐64. ">Woolf 1999</a>). The anxiolytic effects of anticonvulsants may also contribute to pain relief (<a href="./references#CD009950-bbs2-0033" title="SullivanMD , RobinsonJP . Antidepressant and anticonvulsant medication for chronic pain. Physical Medicine and Rehabilitation Clinics of North America2006;17(2):381‐400. ">Sullivan 2006</a>). The mechanisms of action of antidepressants include modulation of inhibitory neurotransmitter pathways via prevention of uptake of noradrenaline and 5‐hydroxytryptamine, as well as up‐regulation of opioid receptor densities and endogenous opioid levels (<a href="./references#CD009950-bbs2-0032" title="SawynokJ , EsserMJ , ReidAR . Antidepressants as analgesics: an overview of central and peripheral mechanisms of action. Journal of Psychiatry and Neuroscience2001;26(1):21‐9. ">Sawynok 2001</a>). </p> </section> <section id="CD009950-sec-0041"> <h3 class="title" id="CD009950-sec-0041">Why it is important to do this review</h3> <p>Pain in GBS is often under treated and poorly managed (<a href="./references#CD009950-bbs2-0027" title="MoulinDE , HagenN , FeasbyTE , AmirehR , HahnA . Pain in Guillain‐Barré syndrome. Neurology1997;48(2):328‐31. ">Moulin 1997</a>). In recent years, a variety of pharmacological treatment options have been investigated in clinical trials for patients with GBS‐associated pain. While studies have shown the possible effectiveness of individual therapies (<a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>; <a href="./references#CD009950-bbs2-0010" title="TripathiM , KaushikS . Carbamezapine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Critical Care Medicine2000;28(3):655‐8. ">Tripathi 2000</a>), in the peer reviewed literature there is no systematic review with meta‐analysis that assesses the efficacy and safety of pharmacological treatment for pain in GBS. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009950-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009950-sec-0042"></div> <p>To assess the efficacy and safety of different pharmacological treatments for various pain symptoms associated with GBS, during both the acute and convalescent (three months or more after onset) phases of GBS. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009950-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009950-sec-0043"></div> <section id="CD009950-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009950-sec-0045"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) and quasi‐RCTs evaluating pharmacological treatment for pain in GBS. For cross‐over trials, an adequate washout period between treatment phases was required for inclusion. At the same time, we attempted to assess whether the order of each treatment phase may affect outcomes where symptoms are expected to improve relatively quickly in acute GBS. Both phases of eligible cross‐over trials were included. We intended to perform sensitivity analysis with exclusion of cross‐over trials from the analysis. </p> </section> <section id="CD009950-sec-0046"> <h4 class="title">Types of participants</h4> <p>Inclusion criteria:</p> <p> <ul id="CD009950-list-0001"> <li> <p>GBS confirmed according to diagnostic criteria (<a href="./references#CD009950-bbs2-0012" title="AsburyAK , CornblathDR . Assessment of current diagnostic criteria for Guillain‐Barré syndrome. Annals of Neurology1990;27 Suppl:S21‐4. ">Asbury 1990</a>); </p> </li> <li> <p>people who explicitly suffered from GBS‐related pain;</p> </li> <li> <p>all ages and both sexes;</p> </li> <li> <p>both acute GBS and convalescent GBS; and</p> </li> <li> <p>all forms of pain associated with GBS, for example neuropathic pain, musculoskeletal pain and visceral pain. </p> </li> </ul> </p> </section> <section id="CD009950-sec-0047"> <h4 class="title">Types of interventions</h4> <p>Experimental intervention: any pharmacological treatment, alone or combined with other treatment. </p> <p>Control intervention: no treatment; placebo alone or combined with other treatment (concomitant interventions would have to be the same in each group); or other pharmacological or non‐pharmacological intervention. We analysed different control groups separately. </p> <p>For the acute phase of GBS, the minimum acceptable duration of treatment for inclusion was one week. For the convalescent phase of GBS, the minimum duration of treatment for inclusion was one month. </p> </section> <section id="CD009950-sec-0048"> <h4 class="title">Types of outcome measures</h4> <p>We included studies that reported pain assessment. We also intended to include studies that did not report pain provided they otherwise satisfied the inclusion criteria and they reported secondary outcome data. If data were available, we collected and analysed the outcomes of all participants initially randomised. We intended to separately measure and analyse the data on the acute and convalescent (three months or more after onset) phases of GBS; however, no studies provided data on the convalescent phase. </p> <section id="CD009950-sec-0049"> <h5 class="title">Primary outcomes</h5> <p>We intended to calculate the number of participants with self reported pain relief of 50% or greater at the endpoint of treatment. The preferred method of pain assessment was pain intensity or change as measured by a visual analogue scale (VAS) or a similarly validated scale (numerical or categorical) that could be converted to a 0 to 100 scale. However, no studies provided such data. </p> </section> <section id="CD009950-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p>We intended to analyse secondary outcomes based on core outcome recommendations from best practice guidelines (<a href="./references#CD009950-bbs2-0015" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. The Journal of Pain2008;9(2):105‐21. ">Dworkin 2008</a>; <a href="./references#CD009950-bbs2-0024" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain‐establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386‐9. '>Moore 2010</a>). We analysed efficacy outcomes using data reported at the end of treatment and safety outcomes from data reported at any time in a participant's treatment. </p> <p> <ol id="CD009950-list-0002"> <li> <p>The number of participants reporting pain relief of 30% or greater (derived using the same pain assessments as the primary outcome). </p> </li> <li> <p>The number of participants reporting global impression of clinical change (PGIC) much or very much improved. </p> </li> <li> <p>The number of participants reporting PGIC very much improved.</p> </li> <li> <p>Mean changes in the score of validated quality of life scales (QOLs).</p> </li> <li> <p>The number of withdrawals due to lack of efficacy.</p> </li> <li> <p>The number of participants experiencing any adverse event.</p> </li> <li> <p>The number of participants experiencing any serious adverse event.</p> </li> <li> <p>The number of withdrawals due to adverse events.</p> </li> </ol> </p> <p>If a statistically significant absolute risk reduction (ARR) existed between interventions, we intended to derive the number needed to treat for an additional beneficial outcome (NNTB) or the number needed to treat for an additional harmful outcome (NNTH) and make direct or indirect comparisons with other interventions when possible. As noted below, no data were reported in any of the included studies for the secondary outcomes 1 through 4. </p> <p>We inserted 'Summary of findings' tables (<a href="./full#CD009950-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD009950-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD009950-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD009950-tbl-0004">summary of findings Table 4</a>) for each comparison and reported primary and secondary outcomes where available. </p> </section> </section> </section> <section id="CD009950-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <p>This search was run for the original review on the 27th August, 2012.</p> <section id="CD009950-sec-0052"> <h4 class="title">Electronic searches</h4> <p>For our updated review we searched the Cochrane Neuromuscular Disease Group Specialized Register (3 November 2014), the Cochrane Central Register of Controlled Trials (CENTRAL 2014, Issue 10 in <i>The Cochrane Library)</i>, MEDLINE (January 1966 to October 2014) and EMBASE (January 1980 to October 2014). </p> <p>The detailed search strategies are included in the appendices: Cochrane Neuromuscular Disease Group Specialized Register <a href="./appendices#CD009950-sec-0098">Appendix 1</a>, CENTRAL (<a href="./appendices#CD009950-sec-0099">Appendix 2</a>), MEDLINE (<a href="./appendices#CD009950-sec-0100">Appendix 3</a>) and EMBASE (<a href="./appendices#CD009950-sec-0101">Appendix 4</a>). </p> <p>In an effort to identify unpublished and ongoing trials, we searched the US National Institutes of Health clinical trial site (<a href="http://www.clinicaltrials.gov/" target="_blank">http://www.clinicaltrials.gov/</a>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/en/" target="_blank">http://www.who.int/ictrp/en/</a>) (<a href="./appendices#CD009950-sec-0102">Appendix 5</a>). </p> </section> <section id="CD009950-sec-0053"> <h4 class="title">Searching other resources</h4> <p>We scanned conference abstracts from the last three years for relevant studies in the World Congress of Neurology (2011, 2013), International Congress on Neuropathic Pain (2010, 2013), Networking World Anesthesia Convention (2012, 2013, 2014) and GBS/Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) International Symposium (2010, 2012, 2014). We checked the reference section of included studies and contacted study authors to identify any additional published or unpublished data. </p> </section> </section> <section id="CD009950-sec-0054"> <h3 class="title" id="CD009950-sec-0054">Data collection and analysis</h3> <section id="CD009950-sec-0055"> <h4 class="title">Selection of studies</h4> <p>Two review authors (JL, LNW) independently evaluated titles and abstracts of identified trials to determine eligibility. We obtained the full text of all potentially relevant studies for further consideration. We resolved any disagreement by discussion, or the third author (EM) arbitrated if necessary. </p> </section> <section id="CD009950-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (JL, LNW) independently extracted eligible data from the published reports onto standardised forms and cross‐checked data for accuracy. The third author (EM) resolved any disagreements regarding data extraction. One author (JL) entered data into the Cochrane statistical software Review Manager 5.1 (<a href="./references#CD009950-bbs2-0030" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>) and the other authors (LNW, EM) checked the accuracy of the data entry. </p> <p>We used checklists to independently record details of the following:</p> <p> <ul id="CD009950-list-0003"> <li> <p>study design;</p> </li> <li> <p>total study duration;</p> </li> <li> <p>methods of generating a randomisation schedule;</p> </li> <li> <p>method of concealment of allocation;</p> </li> <li> <p>blinding;</p> </li> <li> <p>use of an intention‐to‐treat analysis (ITT) (all participants initially randomised would be included in the analyses as allocated to groups); </p> </li> <li> <p>adverse events and dropouts for all reasons;</p> </li> <li> <p>participants (country, number of participants, age, sex, inclusion and exclusion criteria);</p> </li> <li> <p>comparison (details of the intervention in treatment and control groups, details of co‐intervention(s) in both groups, duration of treatment); </p> </li> <li> <p>outcomes and timepoints of measures (number of participants in each group and outcome, regardless of compliance); and </p> </li> <li> <p>factors that influence heterogeneity (sample size, missing participants, confidence intervals and P values in measurement, and subgroup analyses). </p> </li> </ul> </p> </section> <section id="CD009950-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (JL, LNW) independently assessed the risk of bias of all included studies using a domain‐based evaluation (<a href="./references#CD009950-bbs2-0019" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We made critical assessments for each of the following different domains: sequence generation (randomisation), allocation concealment, blinding (of participants and personnel, and of outcome assessors), incomplete outcome data, selective reporting and other bias. We entered our judgement for each domain into a 'Risk of bias' table using the categories 'low risk', 'high risk' or 'unclear risk' (unclear risk indicates either lack of information or uncertainty over the potential for bias). Where possible, we obtained the protocols of included trials or entries in clinical trial registries to assist in the assessment of risk of bias from selective outcome data reporting. </p> </section> <section id="CD009950-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>We attempted to measure the data from all participants initially randomised. We presented dichotomous outcomes as risk ratios (RRs) with 95% confidence intervals (CIs) to express the effect size. When a statistically significant ARR existed between interventions, we derived the NNTB or NNTH. Where dichotomous data were not available, or could not be mathematically derived from continuous data, we expressed continuous outcomes such as VAS pain intensity difference as mean differences (MDs) with 95% CIs. </p> </section> <section id="CD009950-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>We dealt with any unit of analysis issues, such as cluster randomisation, more than one intervention performed in individuals, or multiple observations for the same outcome, according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009950-bbs2-0019" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD009950-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>We used ITT analysis. The ITT population consisted of participants who were randomised and took the assigned study medication. We intended to assign zero improvement for dichotomous outcomes for participants who withdrew due to lack of efficacy or adverse events; however there were no withdrawals in any of the included studies. </p> </section> <section id="CD009950-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>We intended to visually inspect forest plots for evidence of heterogeneity and quantify heterogeneity using the I<sup>2</sup> statistic (<a href="./references#CD009950-bbs2-0019" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). If we found statistically significant heterogeneity (I<sup>2</sup> &gt; 50%), we intended to explore factors for the heterogeneity; however there were insufficient data to perform meta‐analysis. </p> </section> <section id="CD009950-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>If we identified sufficient RCTs (more than 10 studies), we intended to examine potential publication bias using a funnel plot (<a href="./references#CD009950-bbs2-0016" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a>); however only three studies met the inclusion criteria. </p> </section> <section id="CD009950-sec-0063"> <h4 class="title">Data synthesis</h4> <p>We would have analysed and reported data from acute (three months or less from onset) and convalescent (more than three months from onset) phases separately if data had been available. If significant heterogeneity was found (I<sup>2</sup> &gt; 50%), we intended to calculate overall effects using a random‐effects model instead of a fixed‐effect model. Since we were not able to combine outcome data from different studies, we provided a descriptive summary of the results. We analysed different control groups separately. </p> </section> <section id="CD009950-sec-0064"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to analyse subgroups of studies categorised according to baseline differences, such as different kinds of pain (for example neuropathic pain, musculoskeletal pain and visceral pain); different interventions; different control groups; and different dosage and duration of interventions. However, we were not able to perform any of these analyses due to lack of data. </p> </section> <section id="CD009950-sec-0065"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analysis where studies of greater than one month duration but less than 12 weeks were removed, and where cross‐over trials were removed from the analysis. We also intended to examine the robustness of results to fixed‐effect versus random‐effects model assumptions, and the inclusion or exclusion of studies with high risk of bias for a particular domain. However, we were not able to perform any sensitivity analysis due to lack of data. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009950-sec-0066" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009950-sec-0066"></div> <section id="CD009950-sec-0067"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD009950-sec-0113" title="">Characteristics of included studies</a>; <a href="./references#CD009950-sec-0114" title="">Characteristics of excluded studies</a>. </p> <section id="CD009950-sec-0068"> <h4 class="title">Results of the search</h4> <p>From our original review, searches of the electronic databases identified 164 papers in MEDLINE, 182 papers in EMBASE, 7 papers in the Cochrane Neuromuscular Disease Group Specialized Register and 10 papers in CENTRAL. After screening the titles and abstracts, we obtained and assessed full papers of nine articles. Finally, three studies were eligible and were included. On re‐running the searches in 2014, we identified 64 papers after deduplicating the results. We acquired and screened the full text of only one article; this study did not meet inclusion criteria. Agreement between the review authors on exclusion was 100%. We found no relevant ongoing or unpublished trials from our searches of the trials registers (<a href="#CD009950-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD009950-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009950-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009950.pub3/media/CDSR/CD009950/image_n/nCD009950-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009950-sec-0069"> <h4 class="title">Included studies</h4> <p>The three included RCTs (<a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>; <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>; <a href="./references#CD009950-bbs2-0003" title="RutsL , vanKoningsveldR , JacobsBC , vanDoornPA . Determination of pain and response to methylprednisolone in Guillain‐Barré syndrome. Journal of Neurology2007;254(10):1318‐22. [PUBMED: 17426908] ">Ruts 2007</a>) were performed in the acute phase of GBS and enrolled 277 randomised participants. One RCT (<a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>), enrolling 18 participants, was a cross‐over trial with seven days of therapy and a two‐day washout between phases. The other two studies were parallel trials (<a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>; <a href="./references#CD009950-bbs2-0003" title="RutsL , vanKoningsveldR , JacobsBC , vanDoornPA . Determination of pain and response to methylprednisolone in Guillain‐Barré syndrome. Journal of Neurology2007;254(10):1318‐22. [PUBMED: 17426908] ">Ruts 2007</a>). Two trials (<a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>; <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>) enrolled patients from intensive care units in India and administered gabapentin (combined n = 30) for seven days. <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a> also enrolled an arm receiving carbamazepine (n = 12) for seven days. One study (<a href="./references#CD009950-bbs2-0003" title="RutsL , vanKoningsveldR , JacobsBC , vanDoornPA . Determination of pain and response to methylprednisolone in Guillain‐Barré syndrome. Journal of Neurology2007;254(10):1318‐22. [PUBMED: 17426908] ">Ruts 2007</a>) with 223 participants administered methylprednisolone (n = 111) for five days. While the duration of treatment in this study did not meet our pre‐specified inclusion criteria, we made a post hoc decision to include it given that methylprednisolone can be considered a prophylactic treatment and, therefore, was likely to have a duration of action beyond the five days on which it was administered. </p> <p>We provided details of the included trials in the <a href="./references#CD009950-sec-0113" title="">Characteristics of included studies</a> tables. No studies reported data from the convalescent phase of GBS. </p> </section> <section id="CD009950-sec-0070"> <h4 class="title">Excluded studies</h4> <p>We excluded seven studies (<a href="./references#CD009950-bbs2-0004" title="BrisbyH , BalaguéF , SchaferD , SheikhzadehA , LekmanA , NordinM , et al. Glycosphingolipid antibodies in serum in patients with sciatica. Spine2002;27(4):380‐6. ">Brisby 2002</a>; <a href="./references#CD009950-bbs2-0005" title="ForsbergA , PressR , EinarssonU , dePedro‐CuestaJ , Widén HolmqvistL , Swedish Epidemiological Study Group. Impairment in Guillain‐Barré syndrome during the first 2 years after onset: a prospective study. Journal of the Neurological Sciences2004;227(1):131‐8. ">Forsberg 2004</a>; <a href="./references#CD009950-bbs2-0006" title="KorinthenbergR , SchesslJ , KirschnerJ , MöntingJS . Intravenously administered immunoglobulin in the treatment of childhood Guillain‐Barré syndrome: a randomized trial. Pediatrics2005;116(1):8‐14. ">Korinthenberg 2005</a>; <a href="./references#CD009950-bbs2-0007" title="MorgenlanderJC , HurwitzBJ , MasseyEW . Capsaicin for the treatment of pain in Guillain‐Barré syndrome. Annals of Neurology1990;28(2):199. ">Morgenlander 1990</a>; <a href="./references#CD009950-bbs2-0008" title="OdakaM , TatsumotoM , HoshiyamaE , HirataK , YukiN . Side effects of combined therapy of methylprednisolone and intravenous immunoglobulin in Guillain‐Barré syndrome. European Neurology2005;53(4):194‐6. ">Odaka 2005</a>; <a href="./references#CD009950-bbs2-0009" title="SendhilkumarR , GuptaA , NagarathnaR , TalyAB . Effect of pranayama and meditation as an add‐on therapy in rehabilitation of patients with Guillain‐Barré syndrome—a randomized control pilot study. Disability and Rehabilitation2013;35(1):57‐62. ">Sendhilkumar 2013</a>; <a href="./references#CD009950-bbs2-0010" title="TripathiM , KaushikS . Carbamezapine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Critical Care Medicine2000;28(3):655‐8. ">Tripathi 2000</a>) after full‐text evaluation. We provided the reasons for exclusion in <a href="./references#CD009950-sec-0114" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD009950-sec-0071"> <h3 class="title">Risk of bias in included studies</h3> <p>The details of the risk of bias are provided in <a href="#CD009950-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD009950-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Yellow = unclear risk of bias; green = low risk of bias" data-id="CD009950-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009950.pub3/media/CDSR/CD009950/image_n/nCD009950-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Yellow = unclear risk of bias; green = low risk of bias </p> </div> </div> </div> <section id="CD009950-sec-0072"> <h4 class="title">Allocation</h4> <p>Only one RCT (<a href="./references#CD009950-bbs2-0003" title="RutsL , vanKoningsveldR , JacobsBC , vanDoornPA . Determination of pain and response to methylprednisolone in Guillain‐Barré syndrome. Journal of Neurology2007;254(10):1318‐22. [PUBMED: 17426908] ">Ruts 2007</a>) provided details of random sequence generation or allocation concealment. We therefore assigned an unclear risk of bias to the other two RCTs. </p> </section> <section id="CD009950-sec-0073"> <h4 class="title">Blinding</h4> <p>No RCT adequately described methods to ensure double‐blinding. Again, we assigned each study an unclear risk of bias. </p> </section> <section id="CD009950-sec-0074"> <h4 class="title">Incomplete outcome data</h4> <p>No withdrawals or deaths were found in any of the included RCTs. We assigned each study a low risk of bias. </p> </section> <section id="CD009950-sec-0075"> <h4 class="title">Selective reporting</h4> <p>All the pre‐specified outcomes were reported in the results sections of the included studies. We therefore assessed each study as having a low risk of bias. </p> </section> <section id="CD009950-sec-0076"> <h4 class="title">Other potential sources of bias</h4> <p>We did not find any potential publication bias. There were too few trials available for a funnel plot analysis. </p> </section> </section> <section id="CD009950-sec-0077"> <h3 class="title" id="CD009950-sec-0077">Effects of interventions</h3> <p>See: <a href="./full#CD009950-tbl-0001"><b>Summary of findings for the main comparison</b> Gabapentin compared with placebo for pain in Guillain‐Barré syndrome</a>; <a href="./full#CD009950-tbl-0002"><b>Summary of findings 2</b> Carbamazepine compared with placebo for pain in Guillain‐Barré syndrome</a>; <a href="./full#CD009950-tbl-0003"><b>Summary of findings 3</b> Methylprednisolone compared with placebo for pain in Guillain‐Barré syndrome</a>; <a href="./full#CD009950-tbl-0004"><b>Summary of findings 4</b> Gabapentin compared with carbamazepine for pain in Guillain‐Barré syndrome</a> </p> <section id="CD009950-sec-0078"> <h4 class="title">Primary outcome measure</h4> <p>None of the included studies reported results as the number of patients with self reported pain relief of 50% or greater. </p> </section> <section id="CD009950-sec-0079"> <h4 class="title">Secondary outcome measures</h4> <p>1. The number of participants reporting pain relief of 30% or greater (derived using the same pain assessments as the primary outcome). </p> <p>2. The number of participants reporting global impression of clinical change (PGIC) much or very much improved. </p> <p>3. The number of participants reporting PGIC very much improved.</p> <p>4. Mean changes in the score of validated quality of life scales (QOLs).</p> <p>None of the included studies measured or reported outcomes recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT), that is, secondary outcomes 1 through 4 above (<a href="./references#CD009950-bbs2-0015" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. The Journal of Pain2008;9(2):105‐21. ">Dworkin 2008</a>). Therefore, we compared mean or median pain scores as measured by numerical pain rating scales (0 to 10: 0 = no pain, 10 = worst pain) and additional pain outcomes including number of participants developing pain, and analgesic consumption. </p> <section id="CD009950-sec-0080"> <h5 class="title">Pain scores</h5> <p>In <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, participants had significantly lower mean pain scores at the endpoint of the gabapentin phase (day 7) compared to the endpoint of the placebo phase (MD ‐3.61, 95% CI ‐4.12 to ‐3.10, n = 18 in both phases). Of note, while within‐group comparisons were not part of our analysis, pain was lower each day from day 1 to 7 versus baseline (day 0) during the gabapentin phase, decreasing from 7.22 ± 0.83 (mean ± standard deviation) at baseline to 2.06 ± 0.63 on day 7 (P &lt; 0.001 for all comparisons). The decrease in pain scores during the placebo phase was not significant on any day versus baseline (day 0: 7.83 ± 0.78, day 7: 5.67 ± 0.91). </p> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, participants in the gabapentin group (n = 12) had significantly lower median pain scores (3.5, 2.5, 2.0, 2.0, 2.0, 2.0, and 2.0; from day 1 to 7, respectively) on all treatment days in comparison to the placebo (6.0, 6.0, 6.0, 6.0, 6.0, 6.0, and 6.0) (n = 12) and carbamazepine (6.0, 6.0, 5.0, 4.0, 4.0, 3.5, and 3.0) (n = 12) groups (P &lt; 0.05). There were no statistically significant differences in the median pain scores between the carbamazepine and placebo groups from day 1 to day 3 (3.0, 3.0, and 3.0 versus 4.0, 4.0, and 4.0), but from day 4 until the end of the study significantly lower median pain scores were noted in the carbamazepine group (4.0, 4.0, 3.5, and 3.0) compared with placebo (6.0, 6.0, 6.0, and 6.0) (P &lt; 0.05). </p> </section> <section id="CD009950-sec-0081"> <h5 class="title">Number of participants with pain</h5> <p>When intravenous immunoglobulin (IVIg) plus methylprednisolone (n = 111) was compared with IVIg plus placebo (n = 112), after four weeks no significant differences were found in the number of participants with pain (RR 0.89, 95% CI 0.68 to 1.16, P = 0.38), number of participants with decreased pain severity (RR 0.95, 95% CI 0.63 to 1.42, P = 0.80) and number of participants with increased pain severity (RR 0.85, 95% CI 0.52 to 1.41, P = 0.54) (<a href="./references#CD009950-bbs2-0003" title="RutsL , vanKoningsveldR , JacobsBC , vanDoornPA . Determination of pain and response to methylprednisolone in Guillain‐Barré syndrome. Journal of Neurology2007;254(10):1318‐22. [PUBMED: 17426908] ">Ruts 2007</a>). </p> </section> <section id="CD009950-sec-0082"> <h5 class="title">Analgesic consumption</h5> <p>In <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, significant reductions in fentanyl consumption were reported when comparing the gabapentin phase to the placebo phase (n = 18 in both phases) for each day from day 1 to day 7 (P &lt; 0.001 for each day). At day 7 (endpoint) the mean difference in fentanyl consumption was ‐251 µg (95% CI ‐265 to ‐238 µg). </p> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a> on day one, mean fentanyl consumption was lower in both the gabapentin and carbamazepine groups compared to placebo but no difference was found between the gabapentin and carbamazepine groups (n = 12 in all groups). From day two, there were significant differences in fentanyl consumption amongst the three groups, with the lowest consumption in the gabapentin group and the highest in the placebo group (n = 12 in all groups). At the endpoint, a reduction in fentanyl consumption of 225 µg (95% CI ‐249 to ‐200 µg) was found when comparing gabapentin versus placebo; 176 µg (95% CI ‐202 to ‐150 µg) when comparing carbamazepine and placebo; and 48 µg (95% CI ‐71 to ‐26 µg) when comparing gabapentin with carbamazepine (n = 12 in all groups). </p> </section> <section id="CD009950-sec-0083"> <h5 class="title">5.<i>The number of withdrawals due to lack of efficacy</i> </h5> <p>No participants withdrew due to lack of efficacy (or for any other reason) in any of the included studies. </p> </section> <section id="CD009950-sec-0084"> <h5 class="title"><i>6. The number of participants experiencing any adverse event</i> </h5> <p>Two trials (<a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>; <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>) reported adverse events (or lack of). In <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, no significant differences were found in the incidence of nausea (RR 0.50, 95% CI 0.05 to 5.04, P = 0.56) or constipation (RR 0.14, 95% CI 0.01 to 2.54, P = 0.19) between gabapentin and placebo. In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, other than sedation, no adverse events were reported. <a href="./references#CD009950-bbs2-0003" title="RutsL , vanKoningsveldR , JacobsBC , vanDoornPA . Determination of pain and response to methylprednisolone in Guillain‐Barré syndrome. Journal of Neurology2007;254(10):1318‐22. [PUBMED: 17426908] ">Ruts 2007</a> did not describe reporting of adverse events. </p> <p>In <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, there was a significant reduction in mean sedation scores (numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless; 6 = asleep, no response) at the endpoint of the gabapentin phase versus the placebo phase (MD ‐1.19, 95% CI ‐1.52 to ‐0.86), which the authors attributed to reduced requirements for fentanyl in the gabapentin phase. Similarly, in <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a> a significant difference in median sedation scores was recorded during the study period in the gabapentin (2.0 on all days 1 to 7), carbamazepine (3.0, 3.0, 3.0, 3.5, 3.0, 3.0, and 3.0; days 1 to 7, respectively) and placebo (4.0, 4.0, 4.0, 4.0, 4.0, 4.0, and 4.0) groups, again attributed to differences in fentanyl consumption. Participants in the gabapentin and carbamazepine groups had significantly lower sedation scores compared with placebo (P &lt; 0.05). When comparing active interventions, sedation scores were significantly lower in those receiving gabapentin versus those receiving carbamazepine for each day from days 1 to 7 (P &lt; 0.05). </p> </section> <section id="CD009950-sec-0085"> <h5 class="title"><i>7. The number of participants experiencing any serious adverse event</i> </h5> <p>In <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a> and <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a> no participant experienced a serious adverse event. As noted above, <a href="./references#CD009950-bbs2-0003" title="RutsL , vanKoningsveldR , JacobsBC , vanDoornPA . Determination of pain and response to methylprednisolone in Guillain‐Barré syndrome. Journal of Neurology2007;254(10):1318‐22. [PUBMED: 17426908] ">Ruts 2007</a> did not describe reporting of adverse events. There were no deaths reported in any of the studies. </p> </section> <section id="CD009950-sec-0086"> <h5 class="title"><i>8. The number of withdrawals due to adverse events</i> </h5> <p>There were no withdrawals due to adverse events (or for any other reason) in any of the included studies. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009950-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009950-sec-0087"></div> <section id="CD009950-sec-0088"> <h3 class="title" id="CD009950-sec-0088">Summary of main results</h3> <p>Three RCTs enrolling 277 randomised participants were included. Two studies (<a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>; <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>) compared gabapentin with placebo (<a href="./full#CD009950-tbl-0001">summary of findings Table for the main comparison</a>). <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a> was a cross‐over trial with a two‐day washout, which we deemed to be adequate for gabapentin considering its half‐life of five to seven hours. While the study authors primarily reported within‐group changes, between‐group comparisons demonstrated significant reductions in pain and sedation scores at the study endpoint, as well as in fentanyl consumption throughout the study. <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a> reported between‐group comparisons and demonstrated results similar to <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a> in pain scores, sedation scores and analgesic consumption. We were not able to statistically combine the data from these studies due to their nature (cross‐over versus parallel group) and method of data reporting (means versus medians). <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a> also compared carbamazepine with placebo (<a href="./full#CD009950-tbl-0002">summary of findings Table 2</a>) and demonstrated statistically significant reductions in pain (although only after day 3) and fentanyl consumption. One study that we excluded (<a href="./references#CD009950-bbs2-0010" title="TripathiM , KaushikS . Carbamezapine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Critical Care Medicine2000;28(3):655‐8. ">Tripathi 2000</a>) (duration of therapy was only three days) also compared carbamazepine with placebo in a similar population and reported similar reductions in pain and analgesic consumption in the carbamazepine phase. One RCT (<a href="./references#CD009950-bbs2-0003" title="RutsL , vanKoningsveldR , JacobsBC , vanDoornPA . Determination of pain and response to methylprednisolone in Guillain‐Barré syndrome. Journal of Neurology2007;254(10):1318‐22. [PUBMED: 17426908] ">Ruts 2007</a>) compared a five‐day course of methylprednisolone with placebo (with both groups also receiving IVIg) (<a href="./full#CD009950-tbl-0003">summary of findings Table 3</a>). At the four‐week endpoint there were no significant differences in number of participants with pain, number of participants with decreased pain severity, and number of participants with increased pain severity between groups. </p> <p>One RCT (<a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>) compared the active interventions gabapentin and carbamazepine (<a href="./full#CD009950-tbl-0004">summary of findings Table 4</a>) and found that participants receiving gabapentin had significantly reduced pain scores and fentanyl consumption. </p> <p>No significant differences were found in adverse event rates in the gabapentin or carbamazepine groups versus placebo groups. Reductions in sedation scores were thought to be secondary to reductions in opioid consumption, rather than a direct effect of the interventions. </p> </section> <section id="CD009950-sec-0089"> <h3 class="title" id="CD009950-sec-0089">Overall completeness and applicability of evidence</h3> <p>Although significant reductions in pain and sedation scores were observed in those receiving gabapentin and carbamazepine versus placebo, the number of RCTs and participants enrolled were limited. Equally, although the pharmacological interventions studied appeared to be safe, the low number of participants enrolled and the short duration of studies means that safety in larger populations over longer periods of treatment cannot be estimated. Although not explicitly stated, given the participants' symptoms, it appears that no studies reported data from people in the convalescent phase of GBS; therefore no conclusions can be made regarding the efficacy of treatments in this population. </p> </section> <section id="CD009950-sec-0090"> <h3 class="title" id="CD009950-sec-0090">Quality of the evidence</h3> <p>For all the included RCTs, we evaluated the quality of evidence as very low, except for <a href="./references#CD009950-bbs2-0003" title="RutsL , vanKoningsveldR , JacobsBC , vanDoornPA . Determination of pain and response to methylprednisolone in Guillain‐Barré syndrome. Journal of Neurology2007;254(10):1318‐22. [PUBMED: 17426908] ">Ruts 2007</a> where the evidence quality was low. Only one RCT described details of random sequence generation and allocation concealment (<a href="./references#CD009950-bbs2-0003" title="RutsL , vanKoningsveldR , JacobsBC , vanDoornPA . Determination of pain and response to methylprednisolone in Guillain‐Barré syndrome. Journal of Neurology2007;254(10):1318‐22. [PUBMED: 17426908] ">Ruts 2007</a>; <a href="./references#CD009950-bbs2-0034" title="vanKoningsveldR , SchmitzPIM , van derMechéFGA , VisserLH , MeulsteeJ , vanDoornPA , et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain‐Barré syndrome:randomised trial. Lancet2004;363(9404):192‐6. ">van Koningsveld 2004</a>). The numbers of participants enrolled in each trial, with the exception of <a href="./references#CD009950-bbs2-0003" title="RutsL , vanKoningsveldR , JacobsBC , vanDoornPA . Determination of pain and response to methylprednisolone in Guillain‐Barré syndrome. Journal of Neurology2007;254(10):1318‐22. [PUBMED: 17426908] ">Ruts 2007</a>, were very small and the duration of the trials was short (five to seven days of treatment). Moreover, we were unable to perform meta‐analysis because of the nature of the reported data and the heterogeneity of the study designs. <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a> reported pain and sedation scores for each treatment on different days. It did not report any measure of uncertainty for the treatment difference, such as standard error or confidence intervals. Given the crossover nature of the design, neither can be easily estimated; therefore there is insufficient information to include data from this study in a meta‐analysis. The paper does appear to make comparisons between groups at each follow‐up time. However, this is not clearly explained in the paper, and the methods of analysis are not those traditionally employed with crossover trials, casting doubt upon their validity. <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a> is a parallel group study, potentially providing data appropriate for meta‐analysis. However, data are reported as medians and inter‐quartile ranges rather than means and standard deviations (SDs), which are required for meta‐analysis. Although means and SDs can be derived from these values, the reporting of medians and inter‐quartiles suggests that the data are not normally distributed; therefore such derivations may not be appropriate. <a href="./references#CD009950-bbs2-0003" title="RutsL , vanKoningsveldR , JacobsBC , vanDoornPA . Determination of pain and response to methylprednisolone in Guillain‐Barré syndrome. Journal of Neurology2007;254(10):1318‐22. [PUBMED: 17426908] ">Ruts 2007</a> measures pain as a binary outcome (yes/no) rather than on a scale.While the comparisons in this study may be appropriate for inclusion in a meta‐analysis, no other study reported similar data. Last, none of the studies described how GBS was diagnosed. </p> </section> <section id="CD009950-sec-0091"> <h3 class="title" id="CD009950-sec-0091">Potential biases in the review process</h3> <p>Although our search strategy was rigorous, it is possible that certain studies were not identified, for example publications that were not in English and not included in any database we searched. Furthermore, the methodology of the included trials was not clearly described in certain categories, which affected our judgement of the quality of the evidence. </p> </section> <section id="CD009950-sec-0092"> <h3 class="title" id="CD009950-sec-0092">Agreements and disagreements with other studies or reviews</h3> <p>A single consensus review assessed supportive treatments for GBS, which included pain management (<a href="./references#CD009950-bbs2-0021" title="HughesRA , WijdicksEF , BensonE , CornblathDR , HahnAF , MeythalerJM , et al. Supportive care for patients with Guillain‐Barré syndrome. Archives of Neurology2005;62(8):1194‐8. ">Hughes 2005b</a>). In that review, the authors believed carbamazepine or gabapentin may be beneficial for pain in GBS, but the use of opioid analgesics may also be necessary. Therefore, our conclusions with regard to carbamazepine and gabapentin are consistent with the previous consensus review and we have found no data for this systematic review providing evidence for other interventions. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009950-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/media/CDSR/CD009950/urn:x-wiley:14651858:media:CD009950:CD009950-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/media/CDSR/CD009950/image_t/tCD009950-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009950-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009950.pub3/media/CDSR/CD009950/image_n/nCD009950-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/full#CD009950-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/media/CDSR/CD009950/image_n/nCD009950-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009950-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/media/CDSR/CD009950/urn:x-wiley:14651858:media:CD009950:CD009950-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/media/CDSR/CD009950/image_t/tCD009950-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Yellow = unclear risk of bias; green = low risk of bias" data-id="CD009950-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009950.pub3/media/CDSR/CD009950/image_n/nCD009950-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Yellow = unclear risk of bias; green = low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/full#CD009950-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/media/CDSR/CD009950/image_n/nCD009950-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009950-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Gabapentin compared with placebo for pain in Guillain‐Barré syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Gabapentin compared with placebo for pain in Guillain‐Barré syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with pain in Guillain‐Barré syndrome </p> <p><b>Settings:</b> intensive care units in India </p> <p><b>Intervention:</b> gabapentin </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Gabapentin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of patients with self reported pain relief of 50% or greater (not measured)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain score</b> </p> <p>(numerical rating scale of 0 to 10: 0 = no pain, 10 = worst pain)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, mean pain scores decreased from 7.83 ± 0.78 (SD) at baseline (day 0) to 5.67 ± 0.91 on day 7. </p> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median pain scores decreased from 8.0 (1.0 (IQR)) at baseline (day 0) to 6.0 (1.8) on day 7. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, mean pain scores decreased from 7.22 ± 0.83 at baseline to 2.06 ± 0.63 on day 7. </p> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median pain scores decreased from 8.0 (1.0) at baseline (day 0) to 2.0 (0.8) on day 7. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a> </p> <p>mean difference‐3.61 (‐4.12 to ‐3.1) on day 7</p> <p><a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a> </p> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gabapentin superior to placebo in reducing pain scores</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sedation score</b> </p> <p>(numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, mean sedation scores changed from 1.44 ± 0.51 (SD) at baseline (day 0) to 3.63 ± 0.51 on day 7. </p> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median sedation scores changed from 1.0 (1.0 (IQR)) at baseline (day 0) to 4.0 (1.0) on day 7. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, mean sedation scores changed from 1.38 ± 0.50 at baseline to 2.44 ± 0.50 on day 7. </p> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median sedation scores changed from 2.0 (1.0) at baseline to 2.0 (0.0) on day 7. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a> </p> <p>mean difference ‐1.19 (‐1.52 to ‐0.86) on day 7</p> <p><a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a> </p> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gabapentin superior to placebo in reducing sedation scores</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rescue analgesic consumption</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, mean fentanyl consumption change from day 1 to day 7 was ‐3 µg. </p> <p>At day 7, mean fentanyl consumption was 317 ± 24 µg</p> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, mean fentanyl consumption change from day 1 to day 7 was ‐240 µg.<br/> At day 7, mean fentanyl consumption was 351 ± 34 µg. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, mean fentanyl consumption change from day 1 to day 7 was ‐146 µg. </p> <p>At day 7, mean fentanyl consumption was 66 ± 16 µg</p> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, mean fentanyl consumption change from day 1 to day 7 was ‐214 µg. </p> <p>At day 7, mean fentanyl consumption was 126 ± 26 µg.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a> </p> <p>mean difference ‐251 mcg (‐265 to ‐238 mcg) on day 7</p> <p><a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a> </p> <p>‐225 mcg (‐249 to ‐200 mcg) on day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gabapentin superior to placebo in reducing fentanyl consumption</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>111 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b><br/> (6 to 560) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.50 (0.05 to 5.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, no significant<br/> difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Constipation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><br/> (2 to 423) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.14 (0.01 to 2.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From <a href="./references#CD009950-bbs2-0001" title="PandeyCK , BoseN , GargG , SinghN , BaroniaA , AgarwalA , et al. Gabapentin for the treatment of pain in Guillain‐Barré syndrome: a double‐blinded, placebo‐controlled, crossover study. Anesthesia and Analgesia2002;95(6):1719‐23. [PUBMED: 12456446] ">Pandey 2002</a>, no significant<br/> difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IQR</b> : interquartile range; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Insufficient information for random sequence generation and allocation concealment was provided. </p> <p><sup>2</sup> Insufficient information to assess adequacy of methods to ensure blinding. </p> <p><sup>3</sup> Only 54 participants. </p> <p><sup>4</sup> Only 18 participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Gabapentin compared with placebo for pain in Guillain‐Barré syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/full#CD009950-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009950-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Carbamazepine compared with placebo for pain in Guillain‐Barré syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Carbamezapine compared with placebo for pain in Guillain‐Barré syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with pain in Guillain‐Barré syndrome </p> <p><b>Settings:</b> intensive care units in India </p> <p><b>Intervention:</b> carbamazepine </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Carbamazepine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of patients with self reported pain relief of 50% or greater (not measured)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain score</b> </p> <p>(numerical rating scale of 0 to 10: 0 = no pain, 10 = worst pain)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median pain scores decreased from 8.0 (1.0 (IQR) at baseline (day 0) to 6.0 (1.8) on day 7. </p> <p>Median daily scores from day 1 to 7 were 4.0, 4.0, 4.0, 6.0, 6.0, 6.0, and 6.0, respectively).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median pain scores decreased from 8.0 (1.0) at baseline to 3.0 (1.0) on day 7. </p> <p>Daily scores from day 1 to 7 (3.0, 3.0, 3.0, 4.0, 4.0, 3.5, and 3.0, respectively) were significantly lower than placebo from day 4 onwards (P &lt; 0.05). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sedation score</b> </p> <p>(numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median sedation scores changed from 1.0 (1.0 IQR) at baseline (day 0) to 4.0 (1.0) on day 7. </p> <p>Median daily scores from day 1 to 7 were 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, and 4.0, respectively.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median sedation scores changed from 2.0 (1.0) at baseline to 3.0 (1.0) on day 7. </p> <p>Daily scores from day 1 to 7 (3.0, 3.0, 3.0, 3.5, 3.0, 3.0, and 3.0, respectively) were significantly lower than placebo on all days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rescue analgesic consumption</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, mean fentanyl consumption change from day 1 to day 7 was ‐240 µg. </p> <p>At day 7, mean fentanyl consumption was 351 ± 34 µg.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, mean fentanyl consumption change from day 1 to day 7 was ‐ 173 µg. </p> <p>At day 7, mean fentanyl consumption was 174 ± 30 µg.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean difference ‐176 µg (‐202 to ‐150 µg) on day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative effect was calculated at the endpoint. Carbamazepine is superior to placebo in reducing fentanyl consumption </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IQR</b> : interquartile range; <b>SD</b>: standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Insufficient information for random sequence generation and allocation concealment was provided. </p> <p><sup>2</sup> Insufficient information to assess adequacy of methods to ensure blinding. </p> <p><sup>3</sup> Only 24 participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Carbamazepine compared with placebo for pain in Guillain‐Barré syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/full#CD009950-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009950-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Methylprednisolone compared with placebo for pain in Guillain‐Barré syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous immunoglobulin (IVIg) and methylprednisolone compared with IVIg and placebo for pain in Guillain‐Barré syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Guillain‐Barré syndrome, with varying severities of pain </p> <p><b>Settings:</b> hospitals in the Netherlands </p> <p><b>Intervention:</b> IVIg and methylprednisolone </p> <p><b>Comparison:</b> IVIg and placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>IVIg/placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>IVIg/methylprednisolone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of patients with self reported pain relief of 50% or greater (not measured)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with pain after 4 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>518 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>459 per 1000</b><br/> (352 to 601) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.89 (0.68 to 1.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant<br/> difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with decreased pain after 4 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>304 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>288 per 1000</b><br/> (191 to 431) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.95 (0.63 to 1.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant<br/> difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with increased pain after 4 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>232 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>197 per 1000</b><br/> (121 to 327) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.85 (0.52 to 1.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant<br/> difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IQR</b> : interquartile range; <b>IVIg:</b> intravenous immunoglobulin; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Insufficient information to assess adequacy of methods to ensure blinding. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Methylprednisolone compared with placebo for pain in Guillain‐Barré syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/full#CD009950-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009950-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Gabapentin compared with carbamazepine for pain in Guillain‐Barré syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Gabapentin compared with carbamazepine for pain in Guillain‐Barré syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> intensive care unit in India </p> <p><b>Settings:</b> intensive care unit in India </p> <p><b>Intervention:</b> gabapentin </p> <p><b>Comparison:</b> carbamazepine </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Carbamazepine</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Gabapentin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of patients with self reported pain relief of 50% or greater (not measured)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain score</b> </p> <p>(numerical rating scale of 0 to 10: 0 = no pain, 10 = worst pain)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median pain scores from day 1 to day 7 were 6.0, 6.0, 5.0, 4.0, 4.0, 3.5, and 3.0, respectively. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median pain scores from day 1 to day 7 (3.5, 2.5, 2.0, 2.0, 2.0, 2.0, and 2.0) were significantly lower versus carbamazepine on each day (P &lt; 0.05). </p> <p>Baseline pain scores were similar between groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gabapentin may be superior to carbamazepine in reducing pain scores</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sedation score</b> </p> <p>(numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median sedation scores from day 1 to day 7 were 2.0, 3.0, 3.0, 3.0, 3.5, 3.0, 3.0, and 3.0, respectively. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, median sedation scores from day 1 to day 7 (2.0, 2.0, 2.0, 2.0, 2.0, 2.0, and 2.0, respectively) were significantly lower versus carbamazepine on each day (P &lt; 0.05). </p> <p>Baseline sedation scores were similar between groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gabapentin may be superior to carbamazepine in reducing sedation scores</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rescue analgesic consumption</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, mean fentanyl consumption change from day 1 to day 7 was ‐173 µg. </p> <p>At endpoint (day 7), mean fentanyl consumption was 174±30 µg.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD009950-bbs2-0002" title="PandeyCK , RazaM , TripathiM , NavkarDV , KumarA , SinghUK . The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain‐Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia2005;101(1):220‐5. [PUBMED: 15976235] ">Pandey 2005</a>, mean fentanyl consumption change from day 1 to 7 was ‐ 214 µg. </p> <p>At day 7, mean fentanyl consumption was 126 ± 26 µg.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean difference ‐48 µg (‐71 to ‐126 µg) on day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative effect was calculated at the endpoint. Gabapentin is superior to carbamazepine in reducing sedation scores </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Insufficient information for random sequence generation and allocation concealment was provided. </p> <p><sup>2</sup> Insufficient information to assess adequacy of methods to ensure blinding. </p> <p><sup>3</sup> Only 24 participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Gabapentin compared with carbamazepine for pain in Guillain‐Barré syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009950.pub3/full#CD009950-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009950.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009950-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009950-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD009950-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="pt#CD009950-note-0002">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD009950-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD009950-note-0012">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009950-note-0005">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009950\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009950\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009950\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009950\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009950\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009950\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009950\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009950\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009950\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009950\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009950\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009950\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009950\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009950\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009950\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009950\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009950\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009950\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009950.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009950.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009950.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009950.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009950.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716504628"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009950.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716504632"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009950.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918da124e99d9379',t:'MTc0MDcxNjUwNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 